42 results
40-F
2020 FY
EX-99.1
HUGE
FSD Pharma Inc - Ordinary Shares
17 Mar 21
Annual report (Canada)
12:00am
with insurance coverage and reimbursement status for newly-approved pharmaceutical products, which could result in product candidates becoming subject … to unfavourable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, including legislative measures aimed
40FR12B
EX-99.39
HUGE
FSD Pharma Inc - Ordinary Shares
6 Dec 19
Initial registration of securities (Canada)
12:28pm
, the accepted price for the product, the ability to obtain reimbursement at any price and whether we own the commercial rights for that territory, as well … the sales price and the availability of adequate third-party reimbursement;
the cash requirements of any future acquisitions or discovery of product
40-F
2019 FY
EX-99.1
HUGE
FSD Pharma Inc - Ordinary Shares
4 Mar 20
Annual report (Canada)
12:29pm
and the availability of adequate third-party reimbursement;
the cash requirements of any future acquisitions or discovery of product candidates;
the time and cost … reimbursement at any price and whether we own the commercial rights for that territory, as well as the efficiency and availability of any comparable products
40FR12B
EX-99.47
HUGE
FSD Pharma Inc - Ordinary Shares
6 Dec 19
Initial registration of securities (Canada)
12:28pm
, the ability to obtain reimbursement at any price and whether we own the commercial rights for that territory, as well as the efficiency and availability … and the availability of adequate third-party reimbursement;
∙ the cash requirements of any future acquisitions or discovery of product candidates;
∙ the time
20-F
2021 FY
EX-4.14
HUGE
FSD Pharma Inc - Ordinary Shares
31 Mar 22
Annual report (foreign)
8:09am
by the Indemnified Party for (i) indemnification or reimbursement of any Costs, or payment of any Cost Advance, by the Corporation under any … applicable, for the Indemnified Party's reimbursement to the Corporation of any bonus or other incentive-based or equity-based compensation previously
6-K
EX-99.2
o2kqw1il57l pta
3 Aug 20
Current report (foreign)
9:45pm
6-K
EX-99.2
bg1jz7z8oy m8sod
16 Oct 20
FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering
5:21pm
6-K
lmi6it 6p7nqgo
21 Feb 24
Current report (foreign)
8:46pm
40-F
paq5s
17 Mar 21
Annual report (Canada)
12:00am
6-K
EX-99.1
wkk7t1fnc
3 May 21
FSD Pharma Inc. 6-K
7:30am
SUPPL
4xs8n
31 Jul 20
Supplemental materials (foreign)
9:43pm
SUPPL
we99d8hr ay7mc
16 Oct 20
Supplemental materials (foreign)
5:19pm
6-K
EX-99.1
1ox4g8t1r7 5y
5 May 21
Current report (foreign)
11:30am
20-F
j8d5o 6clnmewa0
31 Mar 22
Annual report (foreign)
8:09am
SUPPL
ihxzdh4 kvambc1f
13 Jul 20
Supplemental materials (foreign)
12:00am